Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients With Sepsis-Induced Hypotension. The study aims to evaluate the safety, tolerability, and efficacy of REGN7544 in adult patients with sepsis-induced hypotension, focusing on its effects on blood pressure and vasopressor dosage.
The intervention being tested is REGN7544, an experimental monoclonal antibody designed to treat sepsis-induced hypotension by potentially improving blood pressure and reducing the need for vasopressors.
The study follows a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused, aiming to assess the therapeutic potential of REGN7544.
The study began on May 5, 2025, with the latest update submitted on June 23, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This clinical update could influence Regeneron’s stock performance by boosting investor confidence, especially if the results show promise in treating sepsis-induced hypotension. It also positions Regeneron competitively within the pharmaceutical industry, particularly in the sepsis treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.